Despite community claims, no human study has demonstrated that intramuscular LR3 IGF-1 produces preferential growth in the injected muscle
Yale Medicine physicians recommend the following: Confirm the indication: GLP-1 medications are approved for specific body mass index (BMI) thresholds and medical conditions
However, an excessive ROS level, commonly referred to as oxidative stress, induces damage to deoxyribonucleic acid (DNA), proteins, and lipids, ultimately culminating in cell death [3, 6]
Mounjaro, on the other hand, is the brand name for Tirzepatide, a somewhat newer medication that not only agonizes the GLP-1 receptor but also targets GIP (Glucose-dependent Insulinotropic Polypeptide) receptors, offering a dual mechanism of action